| [1] | Oh, D.-Y., Ruth He, A., Qin, S., et al. (2022). Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1: EVIDoa2200015. DOI:10.1056/EVIDoa2200015. |
| [2] | Lamarca, A., Ross, P., Wasan, H.S., et al. (2020). Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. J. Natl. Cancer Inst. 112: 200−210. DOI:10.1093/jnci/djz071. |
| [3] | Nikanjam, M., Kato, S., and Kurzrock, R. (2022). Liquid biopsy: current technology and clinical applications. J. Hematol. Oncol. 15: 1−14. DOI:10.1186/s13045-022-01351-y. |
| [4] | Xu, Y., Liu, X., Cao, X., et al. (2021). Artificial intelligence: A powerful paradigm for scientific research. The Innovation 2 : 100179. DOI:10.1016/j.xinn.2021.100179. |
| [5] | Egemen, D., Perkins, R.B., Cheung, L.C., et al. (2024). Artificial intelligence-based image analysis in clinical testing: Lessons from cervical cancer screening. J. Natl. Cancer Inst. 116 : 26-33. DOI: 10.1093/jnci/djad202. |
| Zhang N., Piao M., and Zhao H. (2024). Highlights in 2023 ESMO congress biliary tract cancer session. The Innovation Medicine 2(1): 100047. https://doi.org/10.59717/j.xinn-med.2024.100047 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
The five highlights were presented at the ESMO congress BTC session